269
Views
6
CrossRef citations to date
0
Altmetric
Letter

Anti-epidermal growth factor receptor antibody cetuximab in refractory or relapsed multiple myeloma: a phase II prospective clinical trial

, , , , , , , , & show all
Pages 695-697 | Received 15 Dec 2012, Accepted 22 May 2013, Published online: 29 Jul 2013
 

Acknowledgements

The authors would like to thank Andreas Zueiter for excellent documentation assistance.

This work was supported by the Bundesministerium f r Bildung und Forschung (BMBF) [grant 01KN1106]; and by Merck Serono GmbH (grant and drug donation to AE and BvT).

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

BvT and AE received support from Merck Serono GmbH (grant and drug donation).

All remaining authors have declared no conflicts of interest.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.